FDA approves perioperative durvalumab plus neoadjuvant enfortumab vedotin for muscle-invasive bladder cancer

On November 13th 2026, the U.S. Food and Drug Administration (FDA) approved perioperative durvalumab plus neoadjuvant enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).1 Although perioperative cisplatin-based chemotherapy can improve outcomes in MIBC, up to half of patients are ineligible because of renal impairment or other comorbidities. For these patients, radical cystectomy alone has historically remained the main treatment approach, highlighting an unmet need for effective perioperative therapies that can improve outcomes without relying on cisplatin.2

The approval is supported by results from the Phase III VOLGA trial (NCT04960709), which evaluated perioperative durvalumab and neoadjuvant EV, with or without tremelimumab, against radical cystectomy with or without approved adjuvant treatment. Efficacy for perioperative durvalumab plus neoadjuvant EV was assessed in patients with MIBC who were not candidates for cisplatin-based chemotherapy. Dual primary endpoints were event-free survival (EFS) in the durvalumab-EV group and the durvalumab-EV-tremelimumab group, both compared with the control group. A key secondary endpoint was overall survival (OS), and safety was also assessed.3

In the durvalumab plus EV group, both EFS and OS were significantly improved compared with radical cystectomy alone, with a median EFS not reached versus 12.1 months (HR 0.51, 95% CI 0.38–0.67, P<0.0001) and a significant OS benefit (HR 0.58, 95% CI 0.40–0.83, P=0.0027). Median OS was not reached in either group. The 24-month EFS and OS rates were 64% versus 45% and 78% versus 69%, respectively.3

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, who presented the findings of the VOLGA trial at ESMO 2026, comments on the significance of the trial, stating that:

“Overall, when you look at the results of the VOLGA trial with that doublet, you can say this is a new option for patients in this environment. It’s a patient-friendly option, and it’s associated with great outcomes.”

The approval of perioperative durvalumab plus neoadjuvant EV represents an important advance for cisplatin-ineligible patients with MIBC, providing a chemotherapy-sparing approach with the potential to improve long-term disease control in a population with substantial unmet need.


References:

  1. U.S. Food and Drug Administration. FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer. Available here. (Last Accessed 16/11/2026).
  2. AstraZeneca. Perioperative Imfinzi plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer .Available here. (Last Accessed 16/11/2026).
  3. Powles T, Grande E, Simone G, et al. Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial. Abstract LBA2. Presented at the ESMO 2026 Congress; October 23-27, 2026; Madrid, Spain.